Phase I study safety and immunogenicity of vaccination with XAGE1 long peptides in patients with advanced lung adenocarcinoma
- Conditions
- Advanced lung adenocarcinoma
- Registration Number
- JPRN-UMIN000026493
- Lead Sponsor
- Department of Immuno-Oncology, Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10
Not provided
(1) Patients with HIV antibody positive. (2) Patients with HCV antibody positive. (3) Patients with HBs antigen or HBV-DNA positive. (4) Patients with active autoimmune disease. (5) History of serious anaphylaxis induced by antibody preparation. (6) Within 4 weeks after treatment with anticancer agent, immune suppressant, immune enhancer, cytokine therapy, radiotherapy or surgery for the primary disease. (7) Patients with double cancer. (8) Patients who need continuous systemic administration of adrenocorticosteroid. (9) Refuse to use birth control including condom etc. from the time of obtaining the first consent to 24 weeks after the final administration of the study drug (except female after menopause (1 year or more after the last menstruation) and female/male after the operation for sterilization). (10) Patients with active infection. (11) Patients with psychosis or dementia. (12) Patients who have received hematopoietic stem cell transplantation. (13) Any other inadequacy for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method